Moderna, bird flu and mRNA vaccine

Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
U.S. pays $590 million to Moderna to speed up development of bird flu vaccine
The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top priority for the federal government.
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor people with animal exposure.
U.S. Awards $590 Mln To Moderna For MRNA Pandemic Influenza Vaccine Development
The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Is Moderna a Bad-News Buy for 2025?
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...
Why Moderna, Inc. (MRNA) Crashed Last Week
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...